brimonidine tartrate; carbachol · Visus · NDA 220142
Yuvezzi
Earliest generic entry, as listed
10 Nov 2042
Blocked by patent: US 12268662.
Listed patents · 2 unexpired
6 Orange Book listing rows for 2 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 12268662 | drug product, use U-3741, U-4419, U-4420 | 10 Nov 2042 |
| US 12268662 listing row | drug product, use U-3741 · sets the listed date | 10 Nov 2042 |
| US 12268662 listing row | drug product, use U-4419 · sets the listed date | 10 Nov 2042 |
| US 12268662 listing row | drug product, use U-4420 · sets the listed date | 10 Nov 2042 |
| US 8455494 | use U-3741, U-4419, U-4420 | 24 May 2030 |
| US 8455494 listing row | use U-3741 | 24 May 2030 |
| US 8455494 listing row | use U-4419 | 24 May 2030 |
| US 8455494 listing row | use U-4420 | 24 May 2030 |
Exclusivities · 1 unexpired
| NP | new product | 28 Jan 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220142 · 001 · RLD | solution/drops, ophthalmic | 0.1%;2.75% | 10 Nov 2042 |